ocean
uniqu
resourc
provid
divers
array
natur
product
primarili
invertebr
spong
tunic
bryozoan
mollusc
marin
bacteria
cyanobacteria
infecti
diseas
evolv
develop
resist
exist
pharmaceut
marin
environ
provid
novel
lead
fungal
parasit
bacteri
viral
diseas
mani
marin
natur
product
success
advanc
late
stage
clinic
trial
includ
dolastatin
kahalalid
f
aplidin
grow
number
candid
select
promis
lead
extend
preclin
assess
although
mani
marineproduct
clinic
trial
cancer
chemotherapi
drug
resist
emerg
infecti
diseas
threat
bioterror
contribut
interest
assess
natur
ocean
product
treatment
infecti
organ
review
focu
pharmacolog
test
marin
lead
shown
invivo
efficaci
potent
invitro
activ
infecti
parasit
diseas
although
divers
life
terrestri
environ
extraordinari
greatest
biodivers
world
ocean
phyla
life
repres
ocean
cover
earth
surfac
contain
describ
speci
plant
anim
macroscop
plant
anim
adapt
region
ocean
includ
polar
temper
tropic
area
divers
speci
extraordinarili
rich
coral
reef
around
speci
per
area
indopacif
ocean
world
greatest
tropic
marin
biodivers
marin
environ
repres
treasur
use
product
await
discoveri
treatment
infecti
diseas
figur
ecolog
pressur
includ
competit
space
foul
surfac
predat
success
reproduc
led
evolut
uniqu
secondari
metabolit
variou
biolog
activ
import
secondari
metabolit
play
control
infecti
parasit
organ
mani
year
larg
overlook
past
year
marin
plant
anim
focu
worldwid
effort
defin
natur
product
marin
environ
small
number
marin
plant
anim
microb
alreadi
yield
novel
chemic
hundr
new
compound
still
discov
everi
year
discoveri
effort
yield
sever
bioactiv
metabolit
success
develop
pharmaceut
industri
sever
clinic
use
drug
investig
drug
candid
pharmacolog
tool
alreadi
result
marineproduct
discoveri
programm
one
marin
natur
product
current
clinic
investig
potenti
new
anticanc
agent
marin
alkaloid
isol
tunic
ecteinascidia
turbin
ecteinascidin
broadspectrum
antitumour
agent
among
advanc
compound
clinic
applic
review
focu
pharmacolog
test
marin
lead
shown
invivo
efficaci
potent
invitro
activ
infecti
parasit
diseas
includ
malaria
toxoplasmosi
trypanosomiasi
viral
bacteri
fungal
infect
object
highlight
promis
compound
greatest
potenti
lead
clinic
use
treatment
room
review
treatment
specif
infecti
diseas
sever
help
review
antiparasit
drug
antinematod
drug
antituberculosi
agent
antivir
lead
antifung
agent
furthermor
excel
gener
extens
review
focus
marin
natur
product
capon
newman
colleagu
faulkner
antifung
screen
marin
sampl
led
characteris
mani
unpreced
natur
product
regard
antifung
activ
chemic
structur
frequenc
invas
fungal
infect
risen
substanti
increas
number
immunocompromis
patient
infect
hiv
receiv
cancer
chemotherapi
immunosuppress
therapi
treatment
broadspectrum
antibiot
evid
mount
fungi
display
highli
specif
adapt
marin
environ
includ
product
uniqu
secondari
metabolit
fact
marin
organ
contain
secondari
metabolit
differ
terrestri
counterpart
structur
biolog
activ
led
hypothesi
marin
organ
may
contain
effici
antifung
compound
differ
mode
action
select
antifung
activ
compar
human
cell
jasplakinolid
first
exampl
cyclodepsipeptid
isol
spong
figur
identifi
jaspi
sp
collect
fiji
jasplakinolid
also
name
jaspamid
macrocycl
depsipeptid
select
invitro
antimicrobi
activ
minimum
inhibitori
concentr
mic
gml
candida
albican
invivo
topic
activ
solut
jasplakinolid
candida
vagin
infect
mice
similar
miconazol
nitrat
gambier
acid
extrem
potent
antifung
metabolit
isol
strain
epiphyt
marin
dinoflagel
gambierdiscu
toxicu
metabolit
first
antifung
repres
brevetoxintyp
fuse
polyeth
ring
structur
consist
nine
contigu
ether
ring
one
isol
tetrahydrofuran
figur
gambier
acid
inhibit
growth
aspergillu
niger
concentr
ngdisk
potenc
gambier
acid
exce
amphotericin
b
toxic
effect
mice
cultur
mammalian
cell
moder
dose
mgkg
given
intraperiton
inject
addit
marin
natur
product
antifung
activ
list
tabl
antifung
compound
marin
origin
cytotox
consequ
gener
consid
promis
antifung
agent
clinic
applic
review
marin
natur
product
show
potent
antifung
activ
evid
cytotox
avail
mani
case
assess
whether
antifung
activ
outweigh
cytotox
effect
requir
follow
ration
modif
improv
therapeut
index
molecul
search
new
antituberculosi
agent
becom
increasingli
import
emerg
multidrugresist
strain
mycobacterium
tuberculosi
despit
small
number
investig
look
marin
product
potenti
lead
tuberculosi
research
area
product
figur
antiinfect
sea
alkaloid
characteris
complex
heterocycl
ring
system
attach
moieti
first
isol
spong
pachypellina
sp
later
undescrib
petrosiida
genu
alkaloid
exhibit
potent
inhibitori
activ
tuberculosi
mic
gml
like
biogenet
precursor
ircinol
moieti
still
mic
gml
ircinol
repres
use
candid
assess
vivo
tuberculosi
sinc
show
low
cytotox
structur
complex
compar
manzaminetyp
alkaloid
addit
manzamin
inhibit
tuberculosi
mic
gml
cyanosesquiterpen
isol
spong
acanthella
klethra
show
potent
inhibitori
activ
tuberculosi
mic
gml
pseudopteroxazol
benzoxazol
diterpen
alkaloid
isol
west
indian
gorgonian
pseudopterogorgia
elisabetha
induc
growth
inhibit
tuberculosi
concentr
gml
without
substanti
toxic
effect
ergorgiaen
serrulatanebas
diterpen
also
known
bifloran
isol
hexan
extract
west
indian
gorgonian
induc
growth
inhibit
tuberculosi
concentr
gml
litosterol
hydroxysteroid
isol
okinawan
soft
coral
litophyton
viridi
inhibit
growth
tuberculosi
mic
gml
poor
solubl
litosterol
aqueou
tissu
cultur
media
obscur
assess
cytotox
effect
puupehenon
induc
inhibit
tuberculosi
growth
mic
gml
inhibitori
concentr
ic
gml
puupehenon
shikimatesesquiterpen
deriv
metabolit
isol
spong
order
verongida
dictyoceratida
collect
hawaiian
island
anthelmint
activ
anthelmint
drug
use
rid
host
organ
helminth
parasit
parasit
nematod
unseg
worm
constitut
phylum
nematoda
repres
major
issu
commerci
livestock
industri
contribut
substanti
malnutrit
diseas
human
be
particularli
difficult
erad
ascari
lumbricoid
larg
gut
worm
caus
malnutrit
obstruct
bowel
diseas
soiltransmit
bloodsuck
hookworm
ancyclostoma
duodenal
necat
americanu
lead
sever
blood
loss
irondefici
anaemia
decreas
food
intak
impair
digest
malabsorpt
poor
growth
rate
despit
avail
excel
commerci
anthelmint
grow
resist
key
structur
class
benzimidazol
macrolid
necessit
search
new
bioactiv
agent
jasplakinolid
repres
potent
antiparasit
well
antifung
agent
exhibit
invitro
effect
dose
less
gml
nematod
nippostrongylu
braziliensi
respect
tetrahydrofuran
inhibit
develop
egg
infect
freeliv
third
stage
two
speci
degre
nematocid
activ
similar
commerci
avail
nematocid
levamisol
closantel
unfortun
attempt
translat
invitro
nematocid
activ
vivo
prove
unsuccess
surpris
given
hydrophob
properti
drug
howev
understand
invitro
mode
action
compound
may
yet
contribut
discoveri
new
improv
anthelmint
amphilactam
isol
spong
amphimedon
sp
collect
great
australian
bight
featur
unusu
carbon
skeleton
enamino
lacton
lactam
moieti
figur
amphilactam
invitro
nematocid
activ
freeliv
stage
parasit
nematod
h
contortu
ld
gml
substanc
inhibit
larval
develop
stage
littl
activ
nematod
egg
degre
invitro
activ
similar
exist
commerci
anthelmint
levamisol
closantel
thought
merit
invivo
assess
spong
geodia
sp
collect
southern
australia
yield
potent
nematocid
agent
geodin
magnesium
salt
macrocycl
polyketid
lactam
tetram
acid
show
ld
valu
gml
diseas
caus
protozoan
parasit
lead
high
rate
mortal
morbid
worldwid
focus
marinederiv
natur
product
show
promis
efficaci
protozo
infect
caus
leishmania
sp
trypanosoma
sp
toxoplasma
sp
plasmodium
sp
figur
leishmaniasi
diseas
caus
oblig
intracellular
parasit
genu
leishmania
type
diseas
rang
selfheal
ulcer
cutan
leishmaniasi
progress
nasopharyng
infect
mucocutan
leishmaniasi
dissemin
viscer
leishmaniasi
gener
fatal
left
untreat
mediterranean
countri
adult
viscer
leishmaniasi
recognis
aidsrel
opportunist
diseas
larg
due
reactiv
latent
infect
immunosuppress
common
drug
treatment
leishmaniasi
contain
pentaval
antimoni
sodium
stiboglucon
meglumin
antimonit
cardiotox
effect
recommend
dose
consequ
signifi
urgent
need
altern
treatment
spong
genu
plakorti
well
known
product
cyclic
peroxid
two
peroxid
produc
palauan
spong
plakorti
aff
angulospiculatu
activ
leishmania
mexicana
activ
cyclic
peroxid
ld
gml
caus
lysi
cell
membran
h
concentr
gml
strike
decreas
motil
min
peroxid
howev
less
effect
ketoconazol
ld
gml
toxoplasmosi
transmit
human
be
cat
infect
parasit
toxoplasma
gondii
sever
rang
selflimit
adenopathi
fatal
enceph
infect
particularli
danger
pregnant
women
immunocompromis
individu
congenit
infect
infant
fatal
case
new
drug
drug
combin
erad
tissu
cyst
caus
relaps
urgent
need
particularli
patient
intoler
folat
inhibitor
pyrimethamin
trimethoprim
frequent
caus
undesir
sideeffect
remain
group
drug
use
treatment
toxoplasmosi
includ
macrolid
act
tachyzoit
leav
cyst
unaffect
alkaloid
manzamin
display
inhibit
gondii
parasit
gml
concentr
without
cell
toxic
effect
activ
increas
notabl
concentr
gml
gml
even
though
accompani
increas
cytotox
effect
host
cell
therefor
select
invivo
assess
daili
intraperiton
dose
mgkg
manzamin
consecut
day
start
day
infect
prolong
surviv
swiss
webster
mice
day
compar
day
untreat
control
explor
new
manzamin
structureact
relat
studi
studi
optimum
dose
import
improv
invivo
efficaci
manzamin
gondii
sigmosceptrellinb
isol
red
sea
spong
diacarnu
erythraeanu
exhibit
potent
invitro
activ
gondii
concentr
gml
without
sever
toxic
effect
sigmosceptrellinb
activ
inhibit
parasit
human
diploid
fibroblast
cell
cyclic
peroxylacton
plakortid
isol
jamaican
spong
plakinastrella
onkod
potent
invitro
activ
gondii
ic
gml
toxic
effect
host
cell
concentr
gml
flagel
protozoa
trypanosoma
cruzi
trypanosoma
brucei
respect
causal
agent
south
american
trypanosomiasi
chaga
diseas
human
african
trypanosomiasi
sleep
sick
drug
use
treat
diseas
includ
pentamidin
suramin
requir
parenter
administr
effect
earli
haemolymphat
stage
diseas
arsen
drug
melarsoprol
avail
latestag
central
nervou
system
infect
caus
reactiv
encephalopathi
difficult
administ
nitroheterocycl
drug
benznidazol
use
treat
acut
stage
chaga
diseas
effect
chronic
phase
diseas
poorli
toler
clearli
indic
need
new
drug
structur
mechan
action
differ
present
use
green
alga
ulva
sp
endophyt
oblig
marin
fungu
ascochyta
salicornia
isol
cultiv
prepar
scale
produc
structur
unusu
tetram
acid
metabolit
ascosalipyrrolidinon
show
activ
cruzi
mic
gml
wherea
control
benznidazol
mic
gml
main
limit
develop
compound
cytotox
effect
gml
test
rat
skelet
muscl
myoblast
cell
malaria
particularli
seriou
diseas
subsahran
africa
also
seriou
publichealth
issu
certain
region
southeast
asia
south
america
malaria
case
death
caus
parasit
plasmodium
falciparum
sinc
remov
vector
transmiss
anophel
mosquito
almost
imposs
new
antimalari
agent
provid
novel
mechan
action
alway
need
combat
resist
drug
chloroquin
mefloquin
quinin
sulfadoxinepyrimethamin
manzamin
exhibit
potent
invitro
activ
p
falciparum
clone
mic
gml
compar
controldrug
chloroquin
artemisinin
mic
gml
gml
respect
manzamin
inhibit
growth
rodent
malaria
parasit
plasmodium
berghei
vivo
asexu
erythrocyt
stage
p
berghei
inhibit
one
intraperiton
inject
molkg
manzamin
infect
mice
treatment
prolong
surviv
highli
parasitaem
mice
day
compar
day
among
untreat
control
day
among
mice
treat
artemisinin
day
among
mice
treat
chloroquin
recoveri
rate
day
one
inject
oral
administr
oil
suspens
manzamin
also
substanti
reduc
parasitaemia
interestingli
manzamin
hydroxyl
deriv
well
dimer
neokauluamin
extend
live
p
bergheiinfect
mice
far
two
import
human
therapeut
antimalari
drug
administ
one
intraperiton
dose
molkg
manzamin
select
deriv
rapid
onset
action
high
bioavail
sustain
antiparasit
activ
appar
toxic
effect
manzamin
similar
therapeut
index
chloroquin
whose
toxic
dose
molkg
ten
time
higher
dose
requir
molkg
clear
parasit
administ
three
time
interv
effect
manzamin
select
analogu
malaria
make
one
promis
antiinfect
lead
discov
ocean
understand
structureact
relat
uniqu
class
alkaloid
certain
lead
effect
safer
manzaminerel
antimalari
drug
lead
previous
mention
antifung
macrolid
halichondramid
also
notabl
activ
p
falciparum
clone
ic
gml
approach
valu
activ
clinic
use
compound
mefloquin
gml
although
halichondramid
much
lower
select
index
current
use
drug
repres
potenti
new
class
compound
develop
altern
chemotherapi
treatment
malaria
structureact
relat
investig
exampl
marin
secondari
metabolit
contain
isonitril
group
elicit
signific
antimalari
activ
diisocyanoadocian
tetracycl
diterpen
isocycloamphilectan
skeleton
diisocyanoadocian
isol
spong
cymbastela
hooperi
axinellida
halichondrida
display
antiplasmodi
potenc
ic
valu
gml
select
rival
invitro
result
obtain
clinic
use
antimalari
drug
chloroquin
artemisinin
kalihinan
diterpenoid
exhibit
sever
type
biolog
activ
antimalari
activ
kalihinol
noteworthi
kalihinol
isol
okinawan
marin
spong
acanthella
sp
possess
notabl
invitro
antimalari
activ
ec
gml
select
index
si
similar
mefloquin
develop
resist
current
antibacteri
continu
seriou
difficulti
treatment
infecti
diseas
therefor
discoveri
develop
new
antibiot
becom
high
prioriti
review
antiinfect
sea
biomed
research
continu
effort
marin
natur
product
commun
mani
antibacteri
agent
identifi
focus
seem
possess
greatest
potenti
figur
squalamin
first
aminosterol
isol
dogfish
shark
squalu
acanthia
squalida
potent
antimicrobi
activ
mic
gml
staphylococcu
aureu
antiangiogen
antitumour
properti
current
test
clinic
trial
treatment
advanc
nonsmallcel
lung
cancer
cribrostatin
isol
blue
spong
cribrochalina
sp
show
potent
antineoplast
antimicrobi
activ
cribrostatin
potent
inhibitori
activ
neisseria
gonorrhea
mic
gml
cribrostatin
also
activ
penicillinresist
n
gonorrhea
clinic
isol
mic
gml
sphaerococcu
coronopifoliu
cosmopolitan
red
alga
collect
along
atlant
coast
morocco
contain
potent
antibacteri
diterpen
bromosphaeron
show
antibacteri
activ
aureu
mic
gml
marin
fungu
isol
surfac
brown
alga
rosenvingea
sp
genu
pestalotia
collect
bahama
cocultur
unicellular
marin
bacterium
yield
pestalon
pestalon
potent
antibiot
activ
meticillinresist
aureu
mic
gml
vancomycinresist
enterococcu
faecium
mic
gml
result
repres
import
achiev
show
mix
ferment
induc
biosynthesi
novel
antibiot
suggest
method
may
use
drug
discoveri
futur
addit
potenc
agent
toward
drugresist
pathogen
suggest
pestalon
assess
advanc
anim
model
infecti
diseas
jorumycin
dimer
isoquinolin
alkaloid
isol
mantl
mucu
pacif
nudibranch
jorunna
funebri
inhibit
growth
variou
gramposit
bacteriaeg
bacillu
subtili
aureusat
concentr
gml
inhibit
zone
mm
despit
high
potenc
sever
limit
investig
includ
cytotox
effect
ic
gml
difficulti
obtain
pure
stabl
prepar
virus
remain
resist
treatment
prophylaxi
longer
infecti
organ
search
viral
chemotherapeut
agent
marin
sourc
yield
sever
promis
therapeut
lead
report
display
notabl
antivir
activ
figur
perhap
import
antivir
lead
marin
origin
report
thu
far
nucleosid
araa
araa
semisynthet
compound
base
arabinosyl
nucleosid
isol
spong
cryptotethia
crypta
realis
biolog
system
would
recognis
nucleosid
base
modif
sugar
moieti
chemist
began
substitut
typic
pentos
acycl
entiti
substitut
sugar
lead
drug
azidothymidin
zidovudin
araa
vidarabin
arac
cytarabin
acyclovir
azidothymidin
clinic
use
exampl
product
semisynthet
modif
arabinosyl
nucleosid
didemnin
famili
close
relat
cyclic
depsipeptid
obtain
trididemnum
solidum
caribbean
tunic
sea
squirt
famili
didemnida
addit
antitumour
activ
exhibit
signific
invitro
invivo
antivir
properti
canonico
colleagu
report
didemnin
b
invitro
inhibitori
effect
virus
caus
rift
valley
fever
ld
gml
venezuelan
equin
encephalomyel
ld
gml
yellow
fever
ld
gml
invivo
didemnin
b
dose
mgkg
daili
mice
infect
rift
valley
fever
viru
gave
surviv
rate
despit
import
antivir
activ
didemnin
b
cytotox
inhibit
cellular
dna
rna
protein
synthesi
concentr
close
viral
growth
inhibit
henc
low
antivir
select
therapeut
index
didemnin
might
howev
modifi
use
combin
antivir
agent
combat
difficult
diseas
didemnin
b
interfer
mitogen
signal
transmiss
inhibit
kinas
phosphatas
elong
factor
sinc
didemnin
b
subject
phase
clinic
trial
cancer
differ
group
consensu
dose
schedul
use
drug
provid
littl
efficaci
substanti
toxic
effect
eudistomin
repres
larg
famili
alkaloid
isol
shallowwat
tunic
genu
eudistoma
four
type
eudistomin
includ
unsubstitut
pyrrolylsubstitut
pyrrolinylsubstitut
contain
uniqu
condens
oxathiazepin
ring
system
invitro
antivir
potenc
eudistomin
herp
simplex
virus
rang
ngdisk
ngdisk
follow
trend
show
greater
potenc
turn
better
antivir
activ
compound
perri
colleagu
report
isol
investig
structur
mycalamid
new
zealand
spong
mycal
sp
found
materi
consist
mycalamid
effect
coronaviru
vivo
mice
gkg
daili
surviv
day
pure
mycalamid
obtain
inhibit
herp
simplex
viru
polioviru
type
gdisk
mycalamid
b
isol
show
greater
antivir
activ
cytotox
mycalamid
invitro
antivir
test
show
minimum
dose
inhibit
gdisk
mycalamid
b
mycalamid
b
protein
synthesi
inhibitor
antivir
marin
natur
product
present
tabl
unpreced
divers
marin
natur
product
combin
improv
global
awar
need
new
antiinfect
treatment
certain
result
increas
effort
move
product
marin
environ
clinic
applic
although
marineproduct
lead
histor
confront
mani
obstacl
includ
sustain
supplyi
compound
may
account
less
wet
weight
substanti
advanc
suggest
sustain
sourc
achiev
learn
terrestri
drug
lead
continu
exhaust
harvest
natur
reliabl
put
respect
speci
risk
extinct
consequ
largescal
product
metabolit
marin
natur
product
clinic
applic
real
challeng
altern
strategi
environment
sound
econom
feasibl
suppli
clearli
need
tradit
among
first
option
explor
suppli
marinederiv
small
molecul
chemic
synthesi
unfortun
structur
complex
marin
molecul
suggest
novel
mechan
action
high
select
also
result
econom
feasibl
strategi
total
chemic
synthesi
one
success
exampl
synthet
product
marineproduct
drug
unlimit
quantiti
conu
toxin
ziconotid
peptid
natur
second
also
fairli
labourintens
strategi
studi
biolog
role
marin
natur
product
pharmacophor
clearli
defin
structur
moieti
attempt
defin
whether
critic
pharmacophor
via
synthesi
chemic
degrad
modif
combin
result
practic
drug
base
marin
prototyp
aquacultur
sourc
organ
includ
spong
tunic
bryozoan
aim
secur
steadi
suppli
drug
product
progress
notabl
cancer
applic
although
case
biomass
current
gener
still
far
short
requir
marinebas
drug
final
enter
market
furthermor
cultiv
invertebr
natur
environ
subject
sever
uncertainti
destruct
storm
diseas
intrigu
strategi
identifi
true
produc
bioactiv
compound
find
whether
microbi
origin
base
fact
marin
invertebr
harbour
larg
commun
microorgan
includ
bacteria
cyanobacteria
fungi
within
tissu
mani
studi
success
provid
data
support
involv
microorgan
biosynthesi
natur
product
isol
invertebr
major
breakthrough
characteris
microbi
commun
associ
spong
involv
applic
molecular
method
fluoresc
insitu
hybridis
use
groupspecif
rrnatarget
oligonucleotid
probe
approach
led
identif
bacteri
commun
associ
mani
marin
invertebr
review
antiinfect
sea
bacteria
associ
microorgan
produc
compound
interest
care
design
special
media
cultur
would
use
largescal
ferment
current
estim
less
bacteria
seen
marin
sampl
microscop
method
cultiv
standard
condit
result
molecular
approach
offer
particularli
promis
altern
transfer
biosynthet
gene
cluster
vector
suitabl
largescal
ferment
therebi
avoid
difficulti
cultur
symbiot
bacteria
clearli
world
ocean
play
import
part
futur
control
global
infectiousdiseas
burden
although
substanti
progress
made
identifi
novel
drug
lead
ocean
resourc
great
effort
still
need
advanc
clinic
applic
none
declar
man
present
emerg
depart
histori
pain
leftsid
preparotid
swell
comput
tomographi
suggest
lesion
like
tubercul
abscess
figur
sampl
